PharmaCyte Biotech (PMCB) News Today → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free PMCB Stock Alerts $2.10 +0.01 (+0.48%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 9, 2024 | americanbankingnews.comPharmaCyte Biotech (NASDAQ:PMCB) Shares Up 2.4%December 18, 2023 | msn.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 15, 2023 | finance.yahoo.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 5, 2023 | morningstar.comPharmaCyte Biotech Inc PMCBNovember 15, 2023 | markets.businessinsider.comPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | finance.yahoo.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechJune 15, 2023 | msn.comPharmaCyte completes tender offer to purchase sharesJune 15, 2023 | finance.yahoo.comPharmaCyte Biotech Announces Final Results of Tender OfferJune 14, 2023 | bizjournals.comLos Angeles Biotech NewsMay 11, 2023 | finance.yahoo.comPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareApril 21, 2023 | nasdaq.comBiotech ETFs’ Performance Deserves A LookApril 12, 2023 | fortune.com300 biotech and pharma CEOs including the head of Pfizer call for a reversal of the abortion pill banFebruary 2, 2023 | msn.comA 45-year-old biotech CEO may have reduced his biological age by at least 5 years through a rigorous medical program that can cost up to $2 million a year, Bloomberg reportedFebruary 2, 2023 | finance.yahoo.comPharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanOctober 7, 2022 | seekingalpha.comPharmaCyte to evaluate opportunities; CEO steps downOctober 7, 2022 | markets.businessinsider.comPharmaCyte Names Joshua Silverman Interim CEO As CEO Kenneth Waggoner Steps DownAugust 15, 2022 | finance.yahoo.comPharmaCyte Biotech Reaches Cooperation Agreement with Iroquois CapitalJuly 28, 2022 | finance.yahoo.comIroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.July 21, 2022 | finance.yahoo.comPharmaCyte Biotech Commences First Phase of Two-Phase Pig StudyJuly 11, 2022 | finance.yahoo.comIROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORSJuly 11, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022July 5, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap CellsJune 23, 2022 | finance.yahoo.comIROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETINGJune 17, 2022 | stockhouse.comPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueJune 15, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueJune 13, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 2022 BIO International Convention in San DiegoJune 8, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder ValueApril 27, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for DiabetesApril 19, 2022 | marketwatch.comPharmaCyte Biotech Shares Reverse Course, Drop 8%April 19, 2022 | finance.yahoo.comPharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA RequirementsApril 13, 2022 | seekingalpha.comPharmaCyte gets on with preparations for pancreatic cancer trial amid FDA clinical holdApril 13, 2022 | finance.yahoo.comPharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical TrialApril 5, 2022 | finance.yahoo.comPharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of DirectorsMarch 22, 2022 | finance.yahoo.comPharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product CandidateMarch 19, 2022 | marketbeat.comPharmaCyte Biotech (OTCMKTS:PMCB) Raised to Buy at Zacks Investment ResearchZacks Investment Research raised PharmaCyte Biotech from a "hold" rating to a "buy" rating and set a $2.50 price objective for the company in a research note on Saturday.March 18, 2022 | seekingalpha.comPharmaCyte Biotech reports Q3 resultsMarch 16, 2022 | finance.yahoo.comPharmaCyte Biotech Reports Third Quarter Financial Results and Operational HighlightsFebruary 22, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of IntegrationFebruary 16, 2022 | marketbeat.comPharmaCyte Biotech (OTCMKTS:PMCB) Downgraded by Zacks Investment ResearchZacks Investment Research lowered shares of PharmaCyte Biotech from a "buy" rating to a "hold" rating in a research report on Wednesday.February 14, 2022 | finance.yahoo.comPharmaCyte Biotech Updates Status of Investigational New Drug Application to FDAJanuary 11, 2022 | marketbeat.comPharmaCyte Biotech (OTCMKTS:PMCB) Upgraded to "Buy" by Zacks Investment ResearchZacks Investment Research upgraded PharmaCyte Biotech from a "hold" rating to a "buy" rating and set a $2.75 price target on the stock in a research report on Tuesday.January 4, 2022 | finance.yahoo.comPharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated CellsDecember 16, 2021 | benzinga.comPharmaCyte Biotech Reports Q2 2021 Cash On Hand $87MDecember 15, 2021 | finance.yahoo.comPharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational HighlightsOctober 5, 2021 | insidermonkey.com5 Penny Stocks With Long-Term Growth CatalystsSeptember 27, 2021 | finance.yahoo.comPharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNASeptember 21, 2021 | finance.yahoo.comPharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility TestsSeptember 16, 2021 | benzinga.comThinking about buying stock in Camber Energy, Farmmi, Offerpad Solutions, Pharmacyte Biotech, or Barrick Gold?September 16, 2021 | finance.yahoo.comPharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDASeptember 9, 2021 | morningstar.comThinking about buying stock in Globalstar, Pharmacyte Biotech, Humanigen, Kadmon Holdings, or Camber Energy? Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. PMCB Media Mentions By Week PMCB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PMCB News Sentiment▼0.000.51▲Average Medical News Sentiment PMCB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PMCB Articles This Week▼00▲PMCB Articles Average Week Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SNTI News Today AIM News Today APTO News Today EVAX News Today TVGN News Today ZIVO News Today COEP News Today GENE News Today BCDA News Today NKGN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PMCB) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
